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1714protein <0.5 mg/dl), the occurrence of MI remained
greater among those with an elevated ﬁbrinogen
level (deﬁned as creatine kinase-myocardial band >3
times upper limit of normal: 16.2 vs. 1.0%; p ¼ 0.002;
deﬁned as troponin I/T >3 times upper limit of
normal: 27.8% vs. 9.2%, p ¼ 0.007). Longer term
follow-up reveals that the association between
elevated ﬁbrinogen level and occurrence of 6-month
MACE after PCI persists independently of on-
clopidogrel PI or DM (5).
Identifying impaired metabolism of the clopidogrel
prodrug provides an important mechanistic insight
for reduced PI in diabetic patients. Further increased
on-clopidogrel platelet reactivity correlates with dia-
betes and higher coronary atherosclerotic disease
burden and calciﬁcation as detected by angiography
or intravascular ultrasound (IVUS) imaging. However,
the relationship between coronary artery calciﬁcation
and body morphology is more complex, with an in-
verse association reported based on a comprehensive
3-dimensional IVUS-based evaluation. This is of
relevance in diabetic patients who usually have a
higher body mass index. Nevertheless, elevated
serum ﬁbrinogen might be an important mechanistic
and clinical link between the presence of impaired
on-clopidogrel PI, DM with or without systemic
inﬂammation, and the occurrence of MACE after PCI,
especially in patients with a high atherosclerotic
disease burden and greater substrate for athero-
thrombotic events. Although MACE in patients with
CAD are attributable to multiple factors, additional
studies are warranted to evaluate the role of ﬁbrin-
ogen as an independent biomarker, in the absence of
systemic inﬂammation, of long-term outcomes in
patients treated with dual-antiplatelet therapy.Lawrence Ang, MD
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An Independent Link Between Diabetes Mellitus, Impaired
On-Clopidogrel Platelet Inhibition, and Major Adverse
Cardiac Events After Percutaneous Coronary InterventionWe greatly appreciate the positive comments by
Drs. Ang and Mahmud regarding our recent paper,
which providedmechanistic insights into the impaired
response to clopidogrel in patients with diabetes mel-
litus (DM) (1). Drs. Ang andMahmud correctly point out
another key mechanism that may be associated with
adverse outcomes in patients with DM undergoing
percutaneous coronary intervention, which is that
associated with elevated serum ﬁbrinogen levels (2,3).
Indeed, the investigators have pioneered this ﬁeld of
research that has provided important insights into the
complex pathophysiological mechanisms involved
in atherothrombotic complications in DM patients.
Accordingly, in our paper, we acknowledge that mul-
tiple factors, including ﬁbrinogen, are involved in
adverse outcomes in DM patients (1,4). However,
deﬁning the relative contribution of each of these
factors, which may also be patient speciﬁc, remains a
challenge and indeed beyond the scope of mechanistic
studies designed to address a speciﬁc hypothesis. The
goal of our investigation was to delineate mechanisms
involved in the impaired clopidogrel response by
integrating quite complex in vitro and ex vivo
experiments in the setting of a prospective study
including pharmacokinetic and pharmacodynamic
assessments (1). Preliminary work by our group and by
others have set the foundation for the study design
that we used (4,5). We showed that the impaired
platelet inhibitor effects of clopidogrel in DM patients
is largely attributable to attenuation of clopidogrel’s
pharmacokinetic proﬁle, characterized by lower
plasma levels of its active metabolite and only
modestly attributed to altered functional status of the
P2Y12 signaling pathway (1). Indeed, this mechanistic
study is simply 1 piece of a puzzle of an overall very
complex disease status in DM patients. Although other
factors were not addressed, this does not exclude their
important role. Moreover, the observation that not all
DM patients with impaired response to clopidogrel or
J A C C V O L . 6 5 , N O . 1 6 , 2 0 1 5 Letters
A P R I L 2 8 , 2 0 1 5 : 1 7 1 0 – 9
1715even elevated levels of ﬁbrinogen have athero-
thrombotic recurrences further underscores the need
for larger studies aimed at best deﬁning factors
associated with adverse outcomes. This will set the
foundation for dedicated studies not only assessing
the mechanistic role of each of these factors but also
help deﬁne the interplay among them.*Dominick J. Angiolillo, MD, PhD
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DES for Repeat
Revascularization in
Patients With Isolated
Proximal LAD Disease?We read with great interest the paper by Hannan
et al. (1) comparing the clinical outcomes in alarge number of patients with isolated proximal
left anterior descending (PLAD) coronary artery
disease who underwent coronary artery bypass
graft (CABG) surgery and percutaneous coronary
interventions (PCIs) with drug-eluting stents (DES).
They showed that there were no statistically sig-
niﬁcant differences in mortality or mortality, myo-
cardial infarction (MI), and/or stroke between the
CABG and PCI-DES groups, whereas CABG patients
had signiﬁcantly lower repeat revascularization
rates.
Despite the important ﬁndings of the study, there
are some concerns for the clinical application of
these results. First, the type of DES used in the
PCI-DES group was not clariﬁed. New-generation
DES have been proved more effective and safer
than ﬁrst-generation drug-eluting or bare metal
stents (2). Considering this superiority of second-
generation DES, it would be appropriate for study
results to be adjusted for stent type/stent genera-
tion (3).
A study by our group compared the outcomes in
patients with isolated PLAD coronary artery disease
who underwent CABG and PCI with ﬁrst-generation
DES (4). This study showed that there were no
statistically signiﬁcant differences in major adverse
cardiac events (MACE), all-cause mortality, cardiac
death, myocardial infarction, and target vessel revas-
cularization between the 2 groups.
Another issue that emerges from the paper is
the deﬁnition of the endpoints. The use of all-cause
mortality but not cardiac death and stroke or MI
in the complex index of MI/mortality/stroke in
the unmatched patients and propensity-matched
patients analysis may differentiate the ﬁnal results.
Indeed, in the analysis of patients without a previ-
ous MI, when the authors add MI and stroke to the
all-cause mortality, the complex index tends to be
statistically signiﬁcant in favor of CABG (adjusted
hazard ratio: 0.96; 95% conﬁdence interval: 0.86
to 1.06). A table showing the adjusted hazard
ratios for MI, cardiac death, and stroke separately is
needed (5).
The comparison of CABG and PCI-DES in patients
with PLAD coronary disease still remains a contro-
versial issue, especially with second-generation DES
for which further investigation is needed. Until
then, updated guidelines of scientiﬁc associations
and clinicians’ medical criteria deﬁne the appropri-
ateness of the method followed.Ioannis L. Matsoukis, MD
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